CorMedix Inc. · NASDAQ:CRMD

CorMedix — Investor Presentation (September 2020)

21 slides from CorMedix's investor presentation, Sep 1, 2020

  1. Slide 1: Defencath: A potentially new standard-of-care in prevention of catheter related blood stream infections

    Slide 1: Defencath: A potentially new standard-of-care in prevention of catheter related blood stream infections

    DefencathTM: A potentially new standard-of-care in the prevention of catheter related blood stream infections CORMEDIX

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains certain statements that constitute forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Th

  3. Slide 3: Defencath is a Novel Product Targeting Substantial Market Opportunities

    Slide 3: Defencath is a Novel Product Targeting Substantial Market Opportunities

    DefencathTM is a Novel Product Targeting Substantial Market Opportunities • Defencath is a novel catheter lock solution with the potential to change the standard of care in several large markets – no current Novel Product Addressing a pharmacologic agent approved to prevent infections associated wit

  4. Slide 4: CorMedix Senior Management Team

    Slide 4: CorMedix Senior Management Team

    CorMedix Senior Management Team Khoso Baluch Chief Executive Officer EVP and Chief Financial Matt David, MD Officer Phoebe Mounts, PhD, JD EVP and General Counsel Paul Chew, MD Chief Medical Officer Jack Armstrong EVP Technical Operations EVP & Head of Clinical Elizabeth Masson Hurlburt Operations C

  5. Slide 5: Targeting a Substantial Commercial Market Opportunity

    Slide 5: Targeting a Substantial Commercial Market Opportunity

    Targeting a Substantial Commercial Market Opportunity • No pharmacologic agents approved in the U.S. for the prevention of CRBSI in central venous catheters • Total annual cost in U.S. for treating all CRBSI and their complications up to $2.7B • Multiple organizations are focused on reducing CRBSIs

  6. Slide 6: Defencath/Neutrolin is an Anti-Bacterial and Anti-Fungal Catheter Lock Solution

    Slide 6: Defencath/Neutrolin is an Anti-Bacterial and Anti-Fungal Catheter Lock Solution

    DefencathTM/Neutrolin® is an Anti-Bacterial and Anti-Fungal Catheter Lock Solution Designed to Prevent CRBSIs and Clotting • Used to fill catheter lumens when they are not in use to prevent microbial growth and clotting DEFENCATH / NEUTROLIN PROPRIETARY FORMULATION NEUTROLIN/DEFENCATH REGULATORY STA

  7. Slide 7: LOCK-IT-100 – Pivotal Clinical Trial Design

    Slide 7: LOCK-IT-100 – Pivotal Clinical Trial Design

    LOCK-IT-100 – Pivotal Clinical Trial Design • Phase 3, multicenter, double-blind, randomized (1:1), active control (heparin) • Event-driven: 56 CRBSI events required to complete the study; 28 CRBSI events at Interim Analysis met pre-specified DESIGN efficacy endpoint without safety concerns and Data

  8. Slide 8: Phase 3 LOCK-IT-100 – Topline Results

    Slide 8: Phase 3 LOCK-IT-100 – Topline Results

    Phase 3 LOCK-IT-100 – Topline Results  Primary endpoint met – highly statistically significant efficacy  Secondary safety endpoints met - no statistically significant differences between Defencath (D) & Heparin (H) control arm for loss of catheter patency and catheter removal Interim Analysis Full

  9. Slide 9: Phase 3 LOCK-IT-100 – Conclusions

    Slide 9: Phase 3 LOCK-IT-100 – Conclusions

    Phase 3 LOCK-IT-100 – Conclusions LOCK-IT-100, a landmark study, showed that in ESRD subjects with hemodialysis via a 01 central venous catheter, Defencath catheter lock solution significantly reduced catheter- related bloodstream infections by 71% (p=0.0006) in 795 patients (9 D, 32 H). Compared to

  10. Slide 10: Defencath Regulatory Status

    Slide 10: Defencath Regulatory Status

    Defencath Regulatory Status • FDA granted rolling submission and review of Defencath New Drug Application • Ongoing dialogue with FDA on submitted modules • FDA accepted submitted NDA for filing • FDA had 60-day period to review for completeness and to make filing decision • Priority review granted

  11. Slide 11: Defencath Pricing Will be Supported by its Clinical and Economic Benefits

    Slide 11: Defencath Pricing Will be Supported by its Clinical and Economic Benefits

    Defencath Pricing Will be Supported by its Clinical Benefit and Economic Benefits to the Healthcare System Several factors currently being assessed to derive pricing include: 1 In the US, will be the first approved antimicrobial catheter lock solution 2 Facilities and patients involved in at-risk ar

  12. Slide 12: Medicare (CMS) Accounts for ~90% of ESRD Reimbursement

    Slide 12: Medicare (CMS) Accounts for ~90% of ESRD Reimbursement

    Medicare (CMS) Accounts for ~90% of ESRD Reimbursement and is Very Focused on Quality of Care ESRD PPS has quality measures as part of its Payer Mix for Dialysis Coverage reimbursement More Choice Patients methodology 19% Medicare coverage kicks in Quality of Care Measures Medicare Advantage ~1% • E

  13. Slide 13: Defencath Reimbursement Opportunity Through TDAPA

    Slide 13: Defencath Reimbursement Opportunity Through TDAPA

    Defencath Reimbursement Opportunity Through TDAPA Under new regulations effective January 2020, New Chemical Entities (NCEs) are eligible for CMS reimbursement outside the bundle under the TDAPA* program • The intent of the TDAPA is to facilitate beneficiary access to certain new renal dialysis drug

  14. Slide 14: CorMedix Believes Defencath is Eligible for and Will Obtain TDAPA

    Slide 14: CorMedix Believes Defencath is Eligible for and Will Obtain TDAPA

    CorMedix Believes Defencath is Eligible for and Will Obtain TDAPA Highlights of Rationale to Support TDAPA  FDA Fast-Track Designation Unmet Medical Need  FDA Designated as Qualified Infectious Disease Product (QIDP)  No standard of care has been established to prevent CRBSIs in hemodialysis pati

  15. Slide 15: Commercial Execution Can Be Accomplished With a Highly Focused Organization

    Slide 15: Commercial Execution Can Be Accomplished With a Highly Focused Organization

    Commercial Execution Can Be Accomplished With a Highly Focused Organization Map of the standardized incidence rate of ESRD, by Health An initial commercial organization of ~50 people can provide Service Area, in the U.S. population, 2012 - present adequate coverage for launch into hemodialysis: • Th

  16. Slide 16: Label Expansion Into Other CVC Areas Provides Opportunities

    Slide 16: Label Expansion Into Other CVC Areas Provides Opportunities

    Label Expansion Into Other CVC Areas Provides Opportunities; Oncology has Compelling Dynamics • There are multiple natural extension opportunities for Defencath beyond hemodialysis catheters Share with Estimated Patients Market: # of CLS Patient Population Central Venous (2019) per year 2025 • Among

  17. Slide 17: Manufacturing Overview: Supply Chain Substantially Completed

    Slide 17: Manufacturing Overview: Supply Chain Substantially Completed

    Manufacturing Overview: Supply Chain Substantially Completed; Launch Quantities in Production • Successfully concluded technical transfer and validation of the drug product manufacturing process, which has enabled production at 2 different manufacturing locations • Company has DMF for taurolidine; p

  18. Slide 18: Marketing Exclusivity and Intellectual Property

    Slide 18: Marketing Exclusivity and Intellectual Property

    Marketing Exclusivity and Intellectual Property MARKET EXCLUSIVITY • Upon approval, 10.5 years of potential market exclusivity • Designated an Investigational New Drug by FDA • New Chemical Entity (NCE) Status – 5 years of exclusivity • Designated as Qualified Infectious Disease Product (QIDP) – add

  19. Slide 19: Financial Highlights

    Slide 19: Financial Highlights

    Financial Highlights KEY STATISTICS • Exchange: NYSE American (CRMD) • Common Stock: 31.2 million shares as of 8/6/2020 • Market cap: ~$150 million BALANCE SHEET • Cash: $22.4 million as of 6/30/2020 • Pro forma Cash*: $43.9 million as of 6/30/2020 • Debt: None * Inclusive of net proceeds from July

  20. Slide 20: CorMedix Key Highlights

    Slide 20: CorMedix Key Highlights

    CorMedix Key Highlights Defencath is a Novel Anticipating Potential Product Addressing a FDA Approval in Lead Potential for 10.5 Years of Significant Unmet Indication of Market Exclusivity Medical Need Hemodialysis Substantial Market Data Demonstrate Opportunities in Senior Leadership with Effective

  21. Slide 21: CorMedix

    Slide 21: CorMedix

    venous catheter a

Source: Internet Archive copy of cormedix.com

More decks from CorMedix Inc.

All 34 CorMedix decks